Become a Member

written by reader 420 Investors

By SoGiAm, March 25, 2016

This tread is created for serious cannabis investors to share K.A.S.H. by providing ideas, diligence, links, equities, etc. with like-minded individuals.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

645 Comments
Inline Feedbacks
View all comments
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
David B.
David B.
September 19, 2016 11:47 am
Reply to  SoGiAm

Ben, I’m liking $CARA here as well. Do you think that their lead product will be much less addictive than other opioids? The company seems to be making that argument right now as it seemed to not induce any euphoria in animals and the chemical action may not cross the brain barrier.

👍 858
👍 11604
David B.
David B.
September 20, 2016 4:16 pm
Reply to  SoGiAm

I was referring to CARA’s other non-CBD compound that operates on all the opioid receptors, but has been shown to produce no euphoria in animal studies:
$CARA has been on the move over the last week or so. The CARA website does make the claim that its pain killer does not produce euphoria in animal tests, so they think it will be less addictive in humans. Their lead compound is in three different trials: IV post surgical pain, pill form for chronic pain and IV for pruritus (itching).
Here is the brief summary on their website:
CR845

“Cara possesses peripherally-selective molecules that interact with kappa opioid receptors present on peripheral, pain-sensing nerves.

These compounds exhibit potent analgesic and anti-inflammatory properties in animals. Unlike currently marketed opioids, these new compounds do not produce inhibition of intestinal transit (ileus), do not induce life-threatening respiratory depression, nor do they elicit signs of addiction or euphoria in animal models.

The degree of kappa receptor selectivity displayed by CR845 ranks as best-in-class compared to all other previously developed compounds for this therapeutic target. Moreover, CR845 displayed no significant affinity for any other non-opioid known receptors.”

Add a Topic
5155
👍 858
David B.
David B.
September 20, 2016 4:18 pm
Reply to  David B.

CARA is rather unique in that it has CBD related products along with the very promising CR845. I am long CARA as of yesterday.

👍 858
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
👍 11604
1 7 8 9 10 11 21

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
18
0
Would love your thoughts, please comment.x
()
x